Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6

1.

Perceived Barriers and Trends in HPV Vaccination via Patient Survey Responses at Kalamazoo, Michigan's Federally-Qualified Health Center.

VanderVeen N, Wieneke A, Tran S, Kim A, Davis K, Taubel D.

J Community Health. 2019 Aug 7. doi: 10.1007/s10900-019-00719-5. [Epub ahead of print]

PMID:
31392602
2.

Preclinical Efficacy and Safety Profile of Allometrically Scaled Doses of Doxycycline Used to Turn "On" Therapeutic Transgene Expression from High-Capacity Adenoviral Vectors in a Glioma Model.

VanderVeen N, Raja N, Yi E, Appelman H, Ng P, Palmer D, Zamler D, Dzaman M, Lowenstein PR, Castro MG.

Hum Gene Ther Methods. 2016 Jun;27(3):98-111. doi: 10.1089/hgtb.2015.168. Epub 2016 Apr 28.

3.

Marmosets as a preclinical model for testing "off-label" use of doxycycline to turn on Flt3L expression from high-capacity adenovirus vectors.

VanderVeen N, Paran C, Appelhans A, Krasinkiewicz J, Lemons R, Appelman H, Doherty R, Palmer D, Ng P, Lowenstein PR, Castro MG.

Mol Ther Methods Clin Dev. 2014 Feb 5;1. pii: 10.

4.

Preclinical characterization of signal transducer and activator of transcription 3 small molecule inhibitors for primary and metastatic brain cancer therapy.

Assi HH, Paran C, VanderVeen N, Savakus J, Doherty R, Petruzzella E, Hoeschele JD, Appelman H, Raptis L, Mikkelsen T, Lowenstein PR, Castro MG.

J Pharmacol Exp Ther. 2014 Jun;349(3):458-69. doi: 10.1124/jpet.114.214619. Epub 2014 Apr 2.

5.

Effectiveness and preclinical safety profile of doxycycline to be used "off-label" to induce therapeutic transgene expression in a phase I clinical trial for glioma.

VanderVeen N, Paran C, Krasinkiewicz J, Zhao L, Palmer D, Hervey-Jumper S, Ng P, Lowenstein PR, Castro MG.

Hum Gene Ther Clin Dev. 2013 Sep;24(3):116-26. doi: 10.1089/humc.2013.139.

6.

Safety profile, efficacy, and biodistribution of a bicistronic high-capacity adenovirus vector encoding a combined immunostimulation and cytotoxic gene therapy as a prelude to a phase I clinical trial for glioblastoma.

Puntel M, A K M GM, Farrokhi C, Vanderveen N, Paran C, Appelhans A, Kroeger KM, Salem A, Lacayo L, Pechnick RN, Kelson KR, Kaur S, Kennedy S, Palmer D, Ng P, Liu C, Krasinkiewicz J, Lowenstein PR, Castro MG.

Toxicol Appl Pharmacol. 2013 May 1;268(3):318-30. doi: 10.1016/j.taap.2013.02.001. Epub 2013 Feb 9.

Supplemental Content

Loading ...
Support Center